Key Highlights
- Morgan Stanley elevates ARWR rating to Overweight, setting $100 price target versus previous $78
- Critical Phase 3 trial results for plozasiran targeting severe hypertriglyceridemia anticipated Q3 2026
- Bank of America increases price forecast, projecting approximately $3 billion peak revenue opportunity
- Morgan Stanley’s revised forecast sees plozasiran reaching $3.2 billion in peak annual sales, nearly doubling prior $1.7 billion estimate
- ARWR shares gained 8.2% in 2026 and skyrocketed 481% over the trailing twelve-month period
Arrowhead Pharmaceuticals (ARWR) has delivered extraordinary returns to investors, climbing 481% over the past twelve months. The biotech company’s momentum continued Tuesday with a 3.9% gain, pushing shares to $71.92 following Morgan Stanley’s bullish upgrade and enhanced price outlook now set at $100.
Arrowhead Pharmaceuticals, Inc., ARWR
The newly established $100 price objective suggests potential appreciation of roughly 39% from present trading levels. Michael Ulz, analyst at Morgan Stanley, elevated his stance on the biotechnology firm to Overweight from Equal-weight, pointing to forthcoming Phase 3 clinical trial data that he believes will “unlock a multibillion-dollar opportunity that remains underappreciated.”
The primary driver behind this optimistic view centers on plozasiran, Arrowhead’s flagship experimental therapy currently in development for treating severe hypertriglyceridemia (SHTG) — a medical condition characterized by dangerously elevated blood triglyceride levels that significantly increase cardiovascular disease and acute pancreatitis risk.
Investors should mark Q3 2026 on their calendars, when Phase 3 results are scheduled for release. Drawing on earlier clinical data and comparable patient cohort studies, Ulz indicated his expectation for favorable outcomes. Positive trial results would represent a transformative milestone for the organization.
Morgan Stanley wasn’t operating in isolation with its bullish revision. BofA similarly increased its forecast, estimating plozasiran could capture a peak commercial opportunity worth approximately $3 billion within the SHTG indication — signaling growing Wall Street consensus around the therapy’s revenue-generating capacity.
Ulz substantially revised his peak revenue projection upward from $1.7 billion to $3.2 billion. This near-doubling reflects heightened conviction regarding the drug’s potential market penetration, particularly among high-risk patients suffering from pancreatitis.
Competitive Landscape With Ionis
Arrowhead faces meaningful competition in this therapeutic area. Ionis Pharmaceuticals (IONS) is pursuing the same SHTG patient population with its candidate olezarsen. Ulz recognized that Ionis “has set the price” within this market segment.
Olezarsen currently holds approval exclusively for familial chylomicronemia syndrome but has earned Breakthrough Therapy designation from regulators. A supplemental filing is undergoing accelerated regulatory assessment with an anticipated decision deadline of June 30.
Nevertheless, Ulz maintains confidence that the market can support multiple therapies. He views plozasiran as possessing compelling competitive advantages, particularly when targeting the pancreatitis patient subset.
Development Portfolio and Regulatory Submission
Arrowhead filed its inaugural New Drug Application for plozasiran during late 2024. This regulatory submission represented a pivotal evolution for the enterprise — transitioning from a research-oriented biotechnology firm toward establishing commercial operations.
The organization possesses extensive expertise in RNA interference technology. It acquired Roche’s RNAi business assets in 2011, subsequently adding RNAi programs from Novartis in 2015. Johnson & Johnson’s Janssen division maintained a partnership arrangement through 2023, when Janssen restructured away from infectious disease and vaccine development initiatives.
Among the 12 analytical firms monitored by FactSet that provide coverage on ARWR, 10 maintain Buy-equivalent recommendations. Only two firms — Leerink Partners and Bernstein Research — assign Hold ratings.
ARWR shares have advanced 8.2% since the beginning of 2026. In contrast, Ionis has declined 6.2% during the same timeframe, though it posted impressive 156% returns over the past year.
Arrowhead Pharmaceuticals currently commands a market capitalization of $9.94 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
